



Editor-in-Chief
Pedro T Ramirez (USA)

Associate Editors
Anna Fagotti (Italy)
Michael Frumovitz (USA)
Rene Pareja (Colombia)
Anuja Jhingran (USA)

Video Editors
Luis Chiva (Spain)
Houssein El Hajj (France)

Social Media Editors
Andreina Fernandes (Venezuela)
Aarthi S. Jayraj (United Kingdom)

Managing Editor
Emily Hammond (USA)

Editorial Office
International Journal of Gynecological Cancer, BMJ Journals
Two Hudson Square, 3rd Floor,
Hoboken, NJ 07030 USA
E: ijgc@jgeditorial.com

Production Editor
Hannah Martin
E: production.ijgc@bmj.com

Customer support
For general queries and support with
existing and new subscriptions:
W: support.bmj.com
T: +44 (0)20 7111 1105
E: support@bmj.com


Self-archiving and permissions
W: [bmj.com/company/productsservices/
rights-and-licensing/](http://bmj.com/company/productsservices/rights-and-licensing/)
E: bmj.permissions@bmj.com

Disclaimer: The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

Copyright: © 2024 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

Lead Article

- 179** Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study
 *G Cucinella, G Schivardi, X C Zhou, M AlHilli, S Wallace, C Wohlmuth, G Baiocchi, N Tokgozoglu, F Raspagliesi, A Buda, V Zanagnolo, I Zapardiel, N Jagasia, R Giuntoli, A Glickman, M Peiretti, M Lanner, E Chacon, J Di Guilmi, A Pereira, E Laas-Faron, A Fishman, C C Nitschmann, K Kurnit, K Moriarty, A Joehlin-Price, B Lees, A Covens, L De Brot, C Taskiran, G Bogani, F Landoni, T Grassi, C Paniga, F Multinu, L A De Vitis, A Hernández, S Mastroyannis, K Ghoniem, V Chiantera, M Shahi, A J Fought, M McGree, A Mariani, G Glaser*

Editorial

- 188** Isolated tumor cells in low-risk endometrial cancer: are we ready for treatment decisions in 'isolation'?
H-C Hsu, P T Ramirez


Meeting summary

- 190** Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation
M A Angeles, L A De Vitis, G Cucinella, G Bonaldo, N Bizzarri, N Agusti, J Kacperczyk-Bartnik, H El Hajj, C Theofanakis, E Bilir, H-C Hsu, E E Estrada, R Pareja, C Fotopoulou, A du Bois, M Plante, J A Rauh-Hain, M R Mirza, B J Monk, M Gultekin, E Joura, A Fagotti, P T Ramirez

Vaginal Cancer

- 197** TRlmodal DEfinitive invasive vagiNal carcinoma Treatment (TRIDENT protocol): how a standardized approach may change prognostic outcomes
V Lancellotta, G Macchia, G Garganese, B Fionda, D Pezzulla, M De Angeli, R Autorino, T Zinicola, B Gui, L Russo, S M Fragomeni, G Ferrandina, A Rovirosa, E Sala, G Scambia, M A Gambacorta, L Tagliaferri

Cervical Cancer

- 203** SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer
 *D Vázquez-Vicente, F Boria, T Castellanos, M Gutierrez, E Chacon, N Manzour, J A Minguez, N Martin-Calvo, J L Alcazar, L Chiva, SUCCOR Study Group*
- 209** Impact of pelvic radiation therapy in patients with early neuroendocrine cervical carcinoma and no residual disease in the radical hysterectomy specimen: a NeCTuR study
N Khurana, M Frumovitz, A Flores Legarreta, P Ramalingam, A Jhingran, P Bhosale, R Saab, N R R Gonzales, G B Chisholm, G Salvo
- 216** HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix
L Dostalek, P Freitag, M Slovackova, T Zima, M Komarc, L Fricova, T Fucik, K Nemejcova, D Cibula, D Brynda, J Slama

- 224** Incidence of pre-neoplastic and neoplastic lesions of the cervix before and after the COVID-19 pandemic
M Dellino, M Cerbone, F Fortunato, T Capursi, A Lepera, T Mancini, A S Laganà, A Malvasi, P Trerotoli, G Cormio, E Cicinelli, G Cazzato, C Carriero, V Pinto, E Cascardi, A Vitagliano

Uterine Cancer

- 229** Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review
 *L A De Vitis, G Schivardi, G Caruso, C Fumagalli, D Vacirca, M T Achilarré, A Aloisi, A Garbi, V Zanagnolo, G Aletti, E Guerini-Rocco, A Mariani, A Maggioni, M Barberis, G Bogani, N Colombo, F Multinu, I Betella*
- 239** PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer
A Westermann, P Ottevanger, A Reyners, J R Kroep, M G H Van Oijen, R Lalisang, P O Witteveen

- 244** Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features
F Borella, M Mancarella, M Preti, L Mariani, I Stura, A Sciarone, G Bertschy, B Leuzzi, E Piovano, G Valabrega, M Turinetto, I Pino, I Castellano, L Bertero, P Cassoni, S Cosma, D Franchi, C Benedetto

Surgery

- 251** Evaluation of a tiered opioid prescription algorithm in an ERAS pathway: exploring opportunities for further refinement
M S B, T S Suki, M F Munsell, M D Iniesta, J E Garcia Lopez, R T Hillman, K Cain, S Huepenbecker, G Mena, J S Taylor, P T Ramirez, L A Meyer

Ovarian Cancer

- 260** Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done
C Nahshon, Y Segev, M Schmidt, O Lavie

- 267** Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel
S R Kim, L Oldfield, A Tone, A Pollett, S Pedersen, J Wellum, M Cesari, K Lajkosz, T J Pugh, S E Ferguson

- 277** Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy
S Cedillo, C Gan, S Aceituno, L Manso, A C Cercos Lleti, P Ventayol Bosch, A Casado, A Perez Fidalgo

- 285** Prognostic factors in young women with epithelial ovarian cancer: the Young Ovarian Cancer-Care (YOC-Care) study
L Azcona, M Heras, O Arencibia, L Minig, L Marti, A Baciu, J Cespedes, I Niguez, B Gil-Ibanez, B Díaz-Feijoo, L M Melero, J Marcos Sanmartin, J Garcia-Villayzan, B Gomez, M Montesinos, S Herrero, J Gilabert-Estelles, M F Chereguini, M Gorostidi, I Zapardiel, On behalf of YOC-Care Group Collaborative

- 293** Low-grade versus high-grade serous ovarian cancer: comparison of surgical outcomes after secondary cytoreductive surgery
S Cappuccio, C Marchetti, D A Altuntaş, R Oliva, S A Russo, B Costantini, D Giannarelli, L Quagliozzi, G Scambia, A Fagotti

Health & Survivorship

- 300** Development and clinical application of a tool to identify frailty in elderly patients with gynecological cancers
A Ferrero, R Massobrio, M Villa, E Badellino, J O S P Sanjinez, M Giorgi, A Testi, F Govone, D Attianese, N Biglia

Reviews

- 307** Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer
P Parida, G Baburaj, M Rao, S Lewis, R R Damerla
- 317** The microbiome and gynecologic cancer: cellular mechanisms and clinical applications
J Chalif, H Wang, D Spakowicz, A Quick, E K Arthur, D O'Malley, L M Chambers

Clinical trial

- 328** Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial
T Chen, J Xu, B Xia, H Wang, Y Shen

Tumor board

- 332** Synchronous endometrial endometrioid adenocarcinoma and ovarian endometrioid adenocarcinoma
E Rodríguez González, M Deavers, S Chang, A Suri

Corners of the world

- 339** The tug of war: delivering safe gynecologic oncology treatment amid insecurity in Haiti
C Millien, R Henderson, J J Saint Hubert, N D McKenzie, T Randall

Video articles

- 340** Transabdominal resection of the metastatic lymph nodes at the level of the celiac trunk
J Li, J Duan, M Zhu, W Jiang

- 342** Not as easy as it seems: indocyanine green tracking and anatomical variations of sentinel lymph node locations

R P Fernandes, N R Abu-Rustum, C Anton, J P Carvalho

- 344** Complex abdominal wall reconstruction for an isolated parietal recurrence of ovarian cancer

M Montesinos-Albert, P-A Giroux, D Hudry, C Pasquosoone, F Narducci, C Martinez-Gomez

Pathology archives

- 346** Myxoid leiomyosarcoma of the ovary: a very uncommon finding

M Sant'Angelo, A Bartolucci, L Boccione, G Taccagni

Images

- 349** Total uterine inversion due to pedunculated vaginal tumor

M H Castillo, C Marrufó